Upperton CDMO services: ESG investor assessment
An end-to-end GHG approach for a rapidly growing company.
Upperton Pharma Solutions (‘Upperton’) is a UK-based pharmaceutical Contract, Development and Manufacturing Organisation (CDMO services) company that supports drug developers advance medicines from early formulation and clinical supply through to late-stage manufacturing for oral, nasal, pulmonary and parenteral dosage forms.
For the last three years Rawstone has annually calculated Upperton’s GHG emissions. Our robust inventories are used to monitor progress against reduction targets and to ensure continued compliance with Upperton’s investor’s annual ESG assessment. During this time, Upperton has undertaken significant construction work which is not part of their BAU processes and so core to delivery of our service was understanding how this may impact their decarbonisation journey.
Key highlights from the project include:
GHG emissions measurement. Scope 1, 2 and 3 GHG emissions for all relevant categories were measured in accordance with the GHG Protocol and Science Based Target initiative (SBTi) requirements.
GHG target recommendations review. We reviewed Upperton’s current GHG targets against progress and provided recommendations on how these could be revised and expanded (to include scope 3) in a way that both aligns with SBTi best practice and ensures the company’s performance is tracked against a base year that is representative of Upperton’s business operations.
Investor assessment submission. We supported Upperton in completion of the energy and GHG-related questions included in their investor, Inflexion’s, annual ESG assessment.
Working with Rawstone has enabled us to develop our ESG strategy with purpose, identifying our GHG emissions and highlighting where we can continually improve and work towards our reduction targets.
Lorna Patrick, Chief Operating Officer at Upperton.